**Falling Rates of Marijuana Dependence Among Heavy Users**

**Steven Davenport**

**Pardee RAND Graduate School**

doi to published article: https://doi.org/10.1016/j.drugalcdep.2018.06.025

Submitted as manuscript on April 29, 2018

**Abstract**

**Introduction**

Marijuana use has become increasingly popular in the United States since the turn of the century, and typical use patterns among current marijuana users have intensified, raising concerns for an increase in cannabis use disorders (CUDs). Yet the population prevalence of CUDs has mostly remained flat. We analyzed trends in DSM-IV marijuana dependence among Daily/Near-Daily (DND) users, both overall and by age and gender, and considered potential explanations.

**Methods**

Using data assembled from the National Survey on Drug Use and Health (2002-2016), rates of self-reported dependence and constituent symptoms are calculated for DND marijuana users; logistic regressions with pre- and post- periods (2002-2004, 2014-2016) are applied to describe temporal changes.

**Results**

Dependence among DND users fell by 39% (26.5%-16.1%; *p*<0.001). No significant change is detected at the population level. Sub-group analysis shows a steep gradient for age but not for gender. Declines are robust to sub-group analysis, except for users over 50 years old. Among dependence symptoms, most showed significant declines: giving up important activities (*p<0.001)*; continued use despite emotional, mental, or physical problems (*p<0.001)*; failing attempts to reduce use (*p<0.001);* spendinglots of time getting, using, or getting over marijuana (*p*<0.01); and failing to keep limits set on use (*p*<.05). Reported tolerance showed no significant change.

**Conclusions**

Though it is unclear why, the risk of dependence formation among heavy marijuana users appear to have declined substantially since 2002. Further research is warranted to search for explanations related to state marijuana policies, product forms, or social context.

**Key words:** marijuana; cannabis; dependence; United States; National Survey on Drug Use and Health; NSDUH

1. **Introduction**

Since the turn of the century, the United States has seen dramatic changes in marijuana policy, use, and social context. Eight states and the District of Columbia have legalized the possession, use, production, distribution, and sale of marijuana for non-medical use; and more than thirty states have legalized some form of medical marijuana, often sold via dispensaries. Perceptions of the risk of marijuana use have been falling (Pacek et al., 2015), and approval for marijuana legalization has risen to nearly a two-third super majority (Gallup, 2017). Marijuana use has also changed in other ways, such as increasing THC potency, an increasing acceptance and availability of marijuana for medical use, and rising popularity of alternative forms of consumption such as edibles, portable vaporizers, and “dabbing” solid concentrates (Davenport and Caulkins, 2016; Kilmer et al., 2014).

Marijuana use has been on an upward trend since roughly the mid-1990s, and intensifying since 2007 (Carliner et al., 2017). The portion of Americans 12 years or older reporting past-month (“current”) marijuana use rose from 6.2% in 2002 to 8.9% in 2016 (Center for Behavioral Health Statistics and Quality, 2017a)**.** Even among current marijuana users, use habits have intensified, for instance as measured by the portion of past-month users reporting daily or near-daily (“DND”) use, i.e., use on more than 20 of the past 30 days, which tripled from one-in-nine in 1994 to one-in-three in 2014. DND users dominate the marijuana market, accounting for 68% of use days and 60% of expenditures in 2012-2013. In total, the number of days of marijuana use reported to NSDUH increased by more than half from 2002-2003 to 2012-2013 (Davenport and Caulkins, 2016).

Use disorders are an important risk of marijuana use. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) provides definitions of marijuana abuse and dependence, with diagnostic criteria including spending a great time using or getting marijuana, increasing tolerance, continued use despite physical or mental problems, and reduced time spent on important activities; with the notable exclusion of withdrawal symptoms, due to a lack of evidence at the time of publication (American Psychiatric Association, 2000; Hasin et al., 2013). Questions corresponding to these criteria have been asked by the National Survey on Drug Use and Health (NSDUH) for decades, allowing for the calculation of prevalence of cannabis abuse and/or dependence based on self-reported symptoms.

Though the NSDUH questionnaire remains unchanged, the DSM-V has since introduced changes relating to cannabis use disorders (American Psychiatric Association, 2013; Center for Behavioral Health Statistics and Quality, 2016). First, the DSM-V changed the diagnostic threshold for cannabis use disorder, merging cannabis abuse and dependence and changing some criteria: namely, dropping the criterion relating to legality, citing limited information gained for diagnosis and amid doubts about its use as a clinical indicator, and adding a criterion relating to cravings (Peer et al., 2013). Second, reflecting new research, the DSM-V recognized symptoms for cannabis withdrawal, based on feelings of irritability, anger, anxiety, disturbed sleep, decreased appetite, mood, and/or energy, and at least one physical symptom causing significant discomfort, e.g., abdominal pain, tremors, fever, or headache (Hasin et al., 2008). Comparisons suggest these changes have had little effect on the measured prevalence of cannabis use disorders (Mewton et al., 2013; Peer et al., 2013).

NSDUH data suggest four million Americans suffer from DSM-IV marijuana dependence (Center for Behavioral Health Statistics and Quality, 2017a); and as a percent of the general population, marijuana abuse and dependence have remained relatively stable from 2002-2014 at 1.5% (Compton et al., 2016). (However, estimates from the National Epidemiologic Survey on Alcohol and Related Conditions disagree, suggesting a near-doubling from 1.5% to 2.9% (Hasin et al., 2015) .)

One might have expected the population prevalence of marijuana dependence to have increased proportionally to the substantial increase in prevalence of marijuana use. That this did not occur presents a puzzle, which this paper seeks to elaborate. Using National Survey of Drug Use and Health (NSDUH) data, we seek to measure levels and changes in marijuana dependence and its symptomatic criteria among the heaviest users, and consider potential causes at hand.

1. **Methods**
   1. **Data**

Questions corresponding to the DSM-IV diagnostic criteria have been asked by NSDUH since 2002, providing a consistent data source for tracking trends in the reporting of marijuana dependence diagnoses and their constituent symptomatic criteria. NSDUH is a household survey, representative of the U.S. household population aged 12 and older, with over 60,000 respondents per year. Its first year occurred in 2002, when it replaced the National Household Survey on Drug Abuse, marking a new sampling procedure but keeping largely the same questionnaire. NSDUH asks respondents a range of health-related questions, including recent use of different drugs; for marijuana, respondents reporting use within the past-year are asked a series of follow-up items about the recency of use, including a battery of questions corresponding to individual diagnostic criteria provided by the DSM-IV for marijuana abuse and dependence. (NSDUH has not announced changes to its question battery or re-coded variables to incorporate DSM-V criteria.) We assemble these data from 2002 to 2016.

* 1. **Measures**

Our main outcomes are marijuana dependence and its symptomatic criteria, as indicated by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). In accordance with SAMHSA practices following those guidelines, dependence was coded as yes if respondent met at least 3 of the 6 indicated criteria, presented here along with the coded variable(s) in NSDUH: 1) Spent a great deal of time over a period of a month getting, using, or getting over the effects of the substance (MRJLOTTM=1 or MRJGTOVR=1); 2) Unable to keep set limits on substance use or used more often than intended (MRJLIMIT=1 or 2, and MRJKPLMT=2); 3) Needed to use substance more than before to get desired effects or noticed that using the same amount had less effect than before (MRJNDMOR=1 or MRJLSEFX=1); 4) Unable to cut down or stop using the substance every time he or she tried or wanted to (MRJCUTDN=1 or 2, and MRJCUTEV=2); 5) Continued to use substance even though it was causing problems with emotions, nerves, mental health, or physical problems (MRJEMCTD=1 or MRJPHCTD=1); and 6) Reduced or gave up participation in important activities due to substance use (MRJLSACT=1) (Center for Behavioral Health Statistics and Quality, 2017b).

* 1. **Analyses**

Data were weighted to reflect NSDUH’s sampling design, assembled from individual years into an omnibus dataset, and analyzed in R (3.4.2).(SAMHSA) The prevalence among DND users of DSM-IV dependence is calculated for each year of available data, first across all DND users and then by age group (12-17, 18-25, 26-34, 35+) and gender. To provide broader context, levels and changes in DND prevalence are compared to prevalence among past-year marijuana users and among the general population, but detailed results from analyses of non-DND user groups is omitted for brevity. DND prevalence is plotted without alteration, but for sub-group analyses, smoothing is applied in order to reduce year-to-year variation driven by small sample sizes. A simple 5-year moving average is applied (e.g., 2008 = average for 2006-2010) where possible; to conserve data points for plotting, years near the sample’s edge are presented unsmoothed (e.g. 2002, 2016) or partially but symmetrically smoothed (e.g., 2003 = average for 2002-2004). To determine statistical significance, data are divided into pre- (2002-2004) and post- (2014-2016) time periods, and fit with a quasi-binomial regression predicting self-reported DSM-IV dependence as a function of age, race, education, gender, and time period. Change is presented in absolute and relative terms.

Likewise, the prevalence of individual DSM-IV Marijuana Dependence criterion among DND users are calculated, plotted, and tested for statistical significance. No sub-group analysis is undertaken here, for simplicity.

1. **Results**
   1. **Marijuana Dependence**

Rates of marijuana dependence among DND users fell throughout the study period, from a high of 27.3% in 2002 (26.5%, pooling 2002-2004) to a low of 15.8% in 2014 (16.1% for 2014-2016). Among all past-year users, we observe a decline that is similar in relative terms (from 13.8% to 8.5%). Logistic regression confirms the reduction in DND dependence from 2002-2004 to 2014-2016 is statistically significant (*p*<.001). A similar model run on all NSDUH respondents, estimating the population-level prevalence, shows no significant change.

Figure 1 shows DND (dotted black line) and sub-group dependence rates (colored). Sub-group analyses show declines among all age and gender groups, except for adults over 50 years old, among whom dependence has fallen only since 2007, but was increasing beforehand. Dependence rates show a steep age gradient, with adolescent rates roughly doubling those among 26-49 year olds, which in turn double older users’. Rates among females are persistently higher than male rates until crossing in 2015.

**Figure 1. Rates of DSM-IV Dependence Among DND Users and Subgroups**



* 1. **Symptom Criterion**

Among DND users, five of six DSM-IV marijuana dependence symptoms showed significant declines in prevalence. The biggest relative declines are in criterion related to health and lifestyle, e.g., stopping important activities and continued use despite emotional, mental, or physical problems. Reported tolerance (“needed more for the same effect”) showed no significant changes.

**Table 1. DND Prevalence of Dependence and Symptom Criterion**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Condition / Symptom** | **2002-4** | **2014-6** | **P-value** | **Difference** | **Change (%)** |
| DSM-IV MJ Dependence | 26.5 | 16.1 | <0.001\*\*\* | -10.4 | -39.2 |
| Reduced or Gave Up Important Activities | 17.9 | 9.9 | <0.001\*\*\* | -8 | -44.7 |
| Emotional, Mental, or Physical Problems and Continued Use | 15.1 | 8.1 | <0.001\*\*\* | -7 | -46.4 |
| Attempted to Reduce Use but Failed | 15.1 | 10 | <0.001\*\*\* | -5.1 | -33.8 |
| Lots of Time Getting, Using, or Getting Over Marijuana | 73.9 | 63.1 | 0.004\*\*\* | -10.8 | -14.6 |
| Set Limits on Use but Failed to Keep Them | 13.2 | 10.4 | 0.015\*\* | -2.8 | -21.2 |
| Needed More for Same Effect | 44.8 | 40.3 | 0.519 | -4.5 | -10 |

\*\*\* p < .01 \*\*: p < .05 \* p < .1 . p >=.1

1. **Conclusions**

Findings from this paper emphasize that during a period characterized by substantial liberalization in cannabis policy, increases in past-month prevalence, and the intensification of typical use habits, there has been a marked reduction in self-reported rates of marijuana dependence among DND users, from roughly one-in-four to one-in-six. A similar decline in relative terms was observed among past-year users (13.8% to 8.5%). The net effect of these declines, along with increases in baseline use rates, has yielded stable rates of dependence in the broader population. Declines are robust to sub-group analysis by age and gender, with the exception of adults over 50, who show mixed trends.

What may be driving these trends is not entirely clear. The truth lies between two alternative extreme interpretations. One approach takes the trends at face value, inferring that dependence risk of marijuana use has genuinely decreased. A number of factors may be at play. Perhaps increasing social approval of marijuana use has helped DND users to integrate their marijuana use habits with their other commitments, causing fewer to report giving up important activities and fewer problems with family, friends, and co-workers; perhaps as marijuana has become more widely available, DND users are spending less time seeking marijuana; perhaps the spread of less harmful modes of consumption (e.g. vaporizers) or use with the intent to tread health-related issues has led to fewer emotional, mental, or physical problems. Conversely, perhaps the only change has been in users’ propensity to detect problems, attribute them to their cannabis use, and report them – but the underlying risks remain the same. A potential third option concerns a confounder: as marijuana use has spread and normalized, this has driven changes in the composition of the user base (Burns et al., 2013) – perhaps also in characteristics that are not captured in survey data, e.g., users’ general capacity for self-control or deference to social norms.

The spread of new forms of consuming marijuana, namely portable vaporization, “dabbing” of solid concentrates, and consuming edibles, also likely play a role, particularly in areas where medical and recreational marijuana laws have driven sales of these products. (Dried flower has dropped to only 66% of Washington State’s legal marijuana sales by dollar value by mid-2016, and has since continued to fall (Smart et al., 2017).)

As U.S. marijuana policies continue to liberalize, perhaps leading to national legalization, it is especially important that researchers, policymakers, and voters understand the harms of marijuana use – and further, to appreciate these harms may be changing, driven by policy decisions, product characteristics, and social context. The issue merits further research studying how different state marijuana policies or the use of different marijuana products may affect risks of dependence and other health harms. Policy stakes are high, including not only whether marijuana legalization continues to spread to more jurisdictions, but also how harmful aspects of marijuana are perceived and managed within legalized environments.

**References**

American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: Author.

American Psychiatric Association, 2000. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: Author. https://doi.org/10.1073/pnas.0703993104

Burns, R.M., Caulkins, J.P., Everingham, S.S., Kilmer, B., 2013. Statistics on cannabis users skew perceptions of cannabis use. Front. Psychiatry 4, 1–10. https://doi.org/10.3389/fpsyt.2013.00138

Carliner, H., Mauro, P.M., Brown, Q.L., Shmulewitz, D., Rahim-Juwel, R., Sarvet, A.L., Wall, M.M., Martins, S.S., Carliner, G., Hasin, D.S., 2017. The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002–2014. Drug Alcohol Depend. 170, 51–58. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2016.10.042

Center for Behavioral Health Statistics and Quality, 2017a. 2016 National Survey on Drug Use and Health: Detailed Tables.

Center for Behavioral Health Statistics and Quality, 2017b. 2016 National Survey on Drug Use and Health: Methodological summary and definitions. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Center for Behavioral Health Statistics and Quality, 2016. Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Compton, W.M., Han, B., Jones, C.M., Blanco, C., Hughes, A., 2016. Marijuana use and use disorders in adults in the USA, 2002–14: analysis of annual cross-sectional surveys. The Lancet Psychiatry 3, 954–964. https://doi.org/https://doi.org/10.1016/S2215-0366(16)30208-5

Davenport, S.S., Caulkins, J.P., 2016. Evolution of the United States marijuana market in the decade of liberalization before full legalization. J. Drug Issues 46, 411–427. https://doi.org/10.1177/0022042616659759

Gallup, 2017. Record-High Support for Legalizing Marijuana Use in U.S. [WWW Document]. URL http://news.gallup.com/poll/221018/record-high-support-legalizing-marijuana.aspx?g\_source=MARIJUANA&g\_medium=topic&g\_campaign=tiles (accessed 4.26.18).

Hasin, D.S., Keyes, K.M., Alderson, D., Wang, S., Aharonovich, E., Grant, B.F., Author, C., 2008. Cannabis withdrawal in the United States: a general population study. J Clin Psychiatry 69, 1354–1363. https://doi.org/10.4088/JCP.v69n0902

Hasin, D.S., O’Brien, C.P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W.M., Crowley, T., Ling, W., Petry, N.M., Schuckit, M., Grant, B.F., 2013. DSM-5 criteria for substance use disorders: Recommendations and rationale. Am. J. Psychiatry 170, 834–851. https://doi.org/10.1176/appi.ajp.2013.12060782

Hasin, D.S., Saha, T.D., Kerridge, B.T., Goldstein, R.B., Chou, S.P., Zhang, H., Jung, J., Pickering, R.P., Ruan, J., Smith, S.M., Huang, B., Grant, B.F., 2015. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry 72, 1235–1242. https://doi.org/10.1001/jamapsychiatry.2015.1858

Kilmer, B., Everingham, S.S.S., Caulkins, J.P., Midgette, G., Pacula, R.L., Reuter, P.H., Burns, R.M., Han, B., Lundberg, R., 2014. What America’s Users Spend on Illegal Drugs: 2000-2010. Santa Monica, CA: RAND Corporation.

Mewton, L., Slade, T., Teesson, M., 2013. An Evaluation of the Proposed DSM-5 Cannabis Use Disorder Criteria Using Australian National Survey Data. Stud. Alcohol Drugs 74, 614–621. https://doi.org/10.15288/jsad.2013.74.614

Pacek, L.R., Mauro, P.M., Martins, S.S., 2015. Perceived risk of regular cannabis use in the United States from 2002 to 2012: Differences by sex, age, and race/ethnicity. Drug Alcohol Depend. 149, 232–244. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2015.02.009

Peer, K., Rennert, L., Lynch, K.G., Farrer, L., Gelernter, J., Kranzler, H.R., 2013. Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample. Drug Alcohol Depend. 127, 215–219. https://doi.org/10.1016/j.drugalcdep.2012.07.009

Smart, R., Caulkins, J.P., Kilmer, B., Davenport, S., Midgette, G., 2017. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 112, 2167–2177. https://doi.org/10.1111/add.13886

Substance Abuse and Mental Health Services Administration, 2002-2016. National Survey on Drug Use and Health.